TDOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TDOC is not a good buy right now for a Beginner investor with a long-term focus and $50,000-$100,000 to deploy. The stock has some supportive catalysts and improving analyst sentiment, but the business is still showing revenue decline, BetterHelp weakness, and the shares are already overbought after a recent bounce. For an impatient buyer, this is not an attractive entry today; the better call is to hold off rather than buy immediately.
TDOC is in a short-term upward recovery phase, but the setup is stretched. MACD histogram is positive and expanding, which supports near-term momentum, but RSI_6 at 84.459 signals the stock is overbought. Price at 7.47 is sitting near resistance, with R1 at 7.408 and R2 at 7.746, while pivot support is 6.86 and deeper support is 6.311. The moving averages are converging, suggesting a possible trend change, but current price action is extended and not ideal for a fresh long-term entry.
Recent catalysts are constructive: Teladoc announced a Walmart partnership for virtual urgent care, dermatology, and nutrition services, which expands distribution and could improve user acquisition. International revenue grew 17% year over year in Q1, showing that part of the business is still expanding. Analyst sentiment has improved at the margin, with Goldman Sachs raising its target to $8 and keeping Buy, and Deutsche Bank upgrading to Buy with an $11 target. BetterHelp stabilization efforts and AI product plans also provide potential upside if execution improves.
The core negative catalyst is weak operating momentum. Q1 revenue fell 2% year over year to $613.8 million, BetterHelp revenue and paying users both declined 9%, and the company continues to face competition and reimbursement pressure. The stock has lost over 90% over the past five years, which reflects a damaged long-term track record. The latest move higher appears more sentiment-driven than fundamentals-driven, and the elevated RSI suggests the current rally may be overextended.
Latest quarter: Q1 2026. Revenue declined 2% year over year to $613.8 million, showing that top-line growth is still negative. BetterHelp remained a drag with 9% declines in both revenue and paying users, while international revenue increased 17% year over year, offering one of the few clear growth spots. Net loss per share improved slightly, but the overall quarter still points to uneven growth and ongoing business challenges rather than a clean recovery.
Analyst sentiment has improved recently but remains mixed. On the bullish side, Goldman Sachs and Deutsche Bank are Buy-rated with higher targets, and BofA also stayed positive. On the cautious side, Citi is Neutral, Stifel is Hold, Evercore is In Line, Barclays is Equal Weight, and JPMorgan is Neutral. The Wall Street pros view is split: bulls see undervaluation and optionality in BetterHelp/integrated care, while bears focus on slowing growth, competitive pressure, and uncertain execution. Overall, the analyst trend is mildly improving, but not strong enough to make TDOC an obvious long-term buy today.
